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.2012.04.Abstract Background: Fluid resuscitation in early post-operative (PO) period after liver trans-
plantation (LT) can be very detrimental for both graft and patient’s outcome. Central venous pres-
sure (CVP) was commonly used to guide ﬂuid resuscitation after LT; yet, volumetric indices like
stroke volume (SV) or right ventricular end diastolic volume (RVEDV) have gained more support
recently. We tested the hypothesis that use of any of the three parameters to guide ﬂuid therapy in
the early PO period after living donor liver transplantation (LDLT) will not elaborate any changes
in ﬂuid volumes infused or graft and patient outcome.
Patients and methods: Sixty patients undergoing LDLT allocated based on the parameter guiding
the ﬂuid therapy in the ﬁrst 72 h in ICU into one of three groups, G-CVP (control), G-SV and G-
RV groups 20 patients each using CVP, SVI and RVEDVI respectively to guide ﬂuid therapy. Based
on the guiding parameter assessed every 4 h, ﬂuid therapy was administered as 500 ml boluses fol-
lowed by reassessment of the guiding parameter for further ﬂuid infusion. Fluids infused over three
days in the ICU were used as a primary outcome. Hemodynamics, graft and renal functions, and
graft and patient outcome were recorded as secondary objectives.0 10 1497044; fax: +20 50
.
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224 A.M. YassenResults: CVP and PCWP were signiﬁcantly higher in G-SV and G-RV compared to the CVP group
while other hemodynamic parameters did not show signiﬁcant differences between the groups.
Fluid volume infused and urine output were signiﬁcantly higher in G-SV and G-RV compared
to G-CVP group. Laboratory and survival data did not differ among the studied groups.
Conclusion: The use of the CVP to guide ﬂuid infusion after LT is a safe and effective alternative to
more logistically demanding techniques as SV and RVEDVI without any negative impact on
patient hemodynamic or metabolic homeostasis.
ª 2012 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.
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Liver transplantation (LT) is associated with inevitable hemo-
dynamic and volume changes during the operative period that
may extend into the early post-operative (PO) period. Proper
volume replacement protocol in early PO period may be reme-
dial, protecting patients against volume-overload induced
complications especially pulmonary complications [1,2]. Low
central venous pressure (CVP) concept, (CVP < 5 mm Hg)
was adopted to prevent liver congestion by facilitating hepatic
venous drainage and reducing the possibility of bleeding [3–5].
Yet, pressure measurements are always subjected to the inﬂu-
ence of cardiac compliance and vascular resistance jeopardiz-
ing their accuracy and questioning their credibility [6–8].
Recently, several volumetric parameters were tested for superi-
ority over CVP for guiding ﬂuid resuscitation in the intensive
care as stroke volume (SV) and right ventricular end diastolic
volume yet, this is highly demanding since they require the rou-
tine insertion of regular ﬁber-optic pulmonary artery catheter
to measure SV or a special high frequency pulmonary artery
catheter to measure the RVEDV [9]. Previous investigators
tested the association between volume indices and pressure
indices for guiding ﬂuid replacement during early PO period
after several surgical settings [10,11]. Most of these trials en-
rolled patients for cadaveric grafts in whom, the full liver
can better tolerate volume loads without increased risks on
graft functions. None addressed the efﬁcacy of parameters
used to guide ﬂuid therapy exclusively in recipients receiving
partial, living donor grafts We designed this prospective, ran-
domized, controlled, double-blind study to test the hypothesis
that ﬂuid resuscitation guided by CVP, SV or RVEDV will not
lead to signiﬁcant difference in the amount of ﬂuid infused in
the early ICU stay (3 days) in living-donor transplant recipi-
ents as a primary outcome measure. Serum lactate as a surro-
gate of both graft functionality and the impact of use of each
of these parameters on the hemodynamics and transplantation
outcome constituted secondary objectives in this trial.2. Patients and methods
After approval of the local ethical and legal committee, 81 liv-
ing-donor liver transplant (LDLT) recipients admitted for LT
in Mansoura University Liver LT between October 2007 and
January 2011 were assessed for eligibility for this study. Preop-
erative informed consent for enrollment in this randomized
controlled double-blind trial were secured from participating
recipients. The study involved patients of either sex aging be-
tween 30 and 60 years old. Patients with known porto-pulmon-
ary hypertension (diagnosed either preoperatively or intraoperatively), patients with abnormal dimension of right
atrium, right ventricle or left ventricle in preoperative echocar-
diography, patients with any grade II single or multiple valvu-
lar heart diseases or patients who sustained massive bleeding
and blood product transfusion during the intraoperative phase
(more than 10 units of RBCs and fresh frozen plasma) were ex-
cluded from the study. We also excluded patients who came to
the ICU on vasopressors or inotropes. A series of 60 closed
envelopes were prepared including one of the three groups
and for each patient, anesthesia resident picked up a closed
envelops before admitting the patient to the intensive care unit
ICU). Patients were not aware by the applied protocol and
data recording was done by ICU resident who was not aware
of the study protocol. On admission to the ICU, patients al-
ready have an arterial catheter in the left radial artery for inva-
sive blood pressure monitoring and a 7.5-French modiﬁed
continuous thermal ﬁber optic pulmonary artery catheter
(CCO/SvO2/CEDV Edwards Life Science, Irvine, CA, USA)
in the right internal jugular vein. The attending physician con-
ﬁrmed the correct position of the pulmonary artery catheter tip
by ﬂuoroscopy and catheter position is corrected as appropri-
ate. Patient is attached to the ICU monitor (Angstrom AS5
Monitor (Datex – Ohmeda AS5, Microvitec display Ltd., Bol-
ling Road, Bradford, UK)) for monitoring of ECG, invasive
arterial blood pressure, pulse oximetry, central venous pres-
sure (CVP) and pulmonary capillary wedge pressure (PCWP).
For continuous monitoring of mixed venous oxygen saturation
(SvO2), stroke volume index (SVI), cardiac index (CI), right
ventricular end diastolic volume index (RVEDVI), and right
ventricular ejection fraction (RVEF), the pulmonary artery
catheter transducers were attached to a speciﬁc monitor (Vig-
ilance, Edwards Life Science, Irvine, CA, USA). Systemic vas-
cular resistance index (SVRI), pulmonary vascular resistance
index (PVRI), the right ventricular stroke work index
(RVSWI), and the left ventricular stroke work index were cal-
culated from the recorded data. Urine output was recorded
every hour. The study took place during the ﬁrst 72 h in the
ICU. Patients received continuous background infusion of
1000 ml of glucose 10% and 500 ml of RA solutions over
15 h (100 ml h1) as well as mandatory volume for daily drug
administration then, further ﬂuid administration during the
study period took the form of boluses of 500 ml of RA over
60 min. Patients fallen into one of three groups, 20 patients
each, based on the parameter guiding the ﬂuid administration
recorded every 4 h. A trigger value was predetermined for each
of the three parameters based on pilot work in our institute. In
CVP group (G-CVP), patient received ﬂuid boluses if CVP was
64 mm Hg to keep the CVP between 4–5 mm Hg. In stroke
volume group (G-SV), ﬂuid boluses were administered if SVI
recorded was 655 ml m2 beat and in RVEDVI group (G-
Fluid indecis in liver transplantation ICU 225RVV), ﬂuid boluses were administered if RVEDVI recorded
was 6110 ml m2. Thirty minutes after bolus administration,
the controlling parameter is measured and if necessary, an-
other bolus is administered till the desired limit is accom-
plished. Random blood sugar was kept below 150 mg dl with
insulin infusion. Any blood loss was replaced by matching vol-
ume of homologues RBCs and fresh frozen plasma in a ration
of 3–1 to keep hemoglobin above 8 gm dl. Albumin was
infused if serum albumin was less than 3.0 g dl1. When
CVP exceeded 6 mm Hg and urine output was less than
1 ml kg in the last two successive hours, 10 mg of Frisimide
were injected intravenously for graft protection. The primary
outcome parameter in this trial was the amount of ﬂuid infused
over the ﬁrst three ICU days. Secondary objective was to as-
sess the outcome including serum lactate as a surrogate of per-
fusion status and early graft function, renal functions, graft
functions, ICU stay as well as patient and graft survivals.
Hemodynamic data were recorded as an average of 6 daily
readings (every 4 h). Laboratory investigations were
performed through sampling from the arterial line every 12 h
as a part of the routine post-transplant care program. Routine
chest X-ray (PA view) was taken every morning and catheter
position is readjusted under ﬂuoroscopy if needed. Data were
collected by ICU resident who was not aware by the study
protocol.
2.1. Statistical analysis
From the results of pilot work in our center, we assumed to a
mean difference between the studied groups of 40% regarding
the volume of ﬂuid infused in the three postoperative days (col-
lective) to be of clinical signiﬁcance using b-error of 0.1 and
two-tailed a= error of 0.05. A priori sample size estimation
proposed 54 patients in the three groups to be sufﬁcient.
Normality of recorded data was tested using Kolmogorov–
Smirnov test. Continuous data exhibited normal distribution
and were analyzed for statistical differences using two tailed
independent sample Student’s t test with equal variance as-
sumed and presented as mean (SD). Analysis was performed
by Statistical package for social sciences (SPSS) Ver. 17,
New Orchard Road Armonk, New York 10504-1722, USA.
A p value of 0.05 or less was considered signiﬁcant.
3. Results
We assessed 81 patients for eligibility in this trial, 21 were
excluded either for non-meeting the inclusion criteria (17
patients), denying enrollment in the study (2 patients) and
massive blood transfusion (n= 2). Sixty patients were ran-
domized into one of the three study groups 20 patients each.
Three patients were excluded from the study in the G-CVP
group, 2 cases in the G-SV group and 2 patients in the
G-RV group due to protocol violation, so, 53 patients were ﬁ-
nally statistically analyzed (Fig. 1). Patient’s characteristics,
operative data and patient outcome were homogenous among
the studied groups with no baseline differences (Table 1).
Averaged daily hemodynamic data did not show any statisti-
cally signiﬁcant differences apart from the PCWP that were
statistically higher in both G-SV and G-RV groups compared
to G-CVP group during the three PO days (Table 2). Table 3
presents the data of the ﬂuid guiding parameters in the threegroups over the study period. When the volumetric parameters
(SVI and RVEDVI) were used as ﬂuid guiding parameters,
CVP, SVI and RVEDVI were all signiﬁcantly higher in both
G-SV and G-RV groups compared to the G-CVP (Table 3).
No signiﬁcant differences existed between the laboratory pro-
ﬁles of patients in the studied groups neither did the serum
lactate (Table 4, Fig. 2 and 3). Fig. 4 illustrates the total vol-
ume of ﬂuids infused daily and the daily urine output in the
studied groups. In G-RV and G-SV groups, the volume of
ﬂuid infused and the urine output daily were signiﬁcantly high-
er compared to the G-CVP group and by day three, the ﬂuid
infused in G-RV group was also signiﬁcantly larger compared
to the G-SV group (p= 0.01) (Fig. 4).
4. Discussion
Our null hypothesis was rejected. The use of volumetric
parameters (SVI and RVSWI) to guide the ﬂuid infusion in
the early PO period after LT invited more ﬂuid volume com-
pared to the traditional use of CVP without affecting neither
graft nor patient outcomes in this trial.
During the operative phase of LT, ﬂuids are sequestered
into the third space, this effect also persists in the stressful
early PO period and may even be augmented by the immuno-
suppression protocol that favors salt and water retention
necessitating the adoption of a ﬂuid infusion protocol that
maintains stable hemodynamics while achieving a negative
ﬂuid balance to recruit the excess ﬂuid from the third space
into the central circulation [1,12]. Previous investigators com-
pared several parameters to assess preload and test ﬂuid
responsiveness during liver transplantation who may be over-
load intolerant [13,14]. Yet, no speciﬁc research was conducted
in the early PO period after LDLT. This is particularly impor-
tant as during LDLT, the venous drainage of the graft consti-
tutes a major challenge due to venous reconstruction using the
donor’s native right hepatic vein and segmental veins instead
of the wider diameter common hepatic nein. Yet, the reduced
sized graft still receives the entire portal ﬂow from the recipient
splanchnic circulation. Adoption of a low CVP is a graft-sav-
ing technique in which, keeping the CVP around 4–5 mm Hg
helps facilitating the venous drainage of the graft at this early
phase until the portal pressure starts to fad during the next PO
days [15].
In our trial, ﬂuid administration guided by either SVI or
RVEDVI led to signiﬁcantly higher CVP and PCWP in G-
SV and G-RV groups compared to G-CVP group. This in-
crease in the ﬁlling pressures could be attributed to the signif-
icantly larger ﬂuid volume infused in both G-SV and G-RV
groups compared to that infused in G-CVP group. Other
hemodynamic data, in our trial, support this assumption. Fill-
ing pressures depends not only of preload, but also on myocar-
dial compliance and afterload status. The absence of any
signiﬁcant differences between the study groups in systemic
and pulmonary vascular resistance strongly nullify the possi-
bility of contribution of vascular resistance in generating this
increase in the pressure parameters (CVP and PCWP). Mean-
while, Siniscalchi and his co-investigators stated that the right
ventricular contractility is not altered in uncomplicated liver
transplantation which also excludes the involvement of early
cardiac contractile abnormalities as a precursor for such in-
crease in the cardiac ﬁlling pressures [16]. RVEF and SV,
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Excluded (n=21) 
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Figure 1 CONSORT patient’s ﬂow diagram.
Table 1 Patient characteristics, operative data and outcome parameters of G-CVP, (n= 17), G-SV (n= 18 and G-RV (n= 18)
groups.
G-CVP, n= 17 G-SV, n= 18 G-RV, n= 18
Age (years) 49.8 ± 10.5 50.9 ± 7.9 48.1 ± 5.3
Male gender (%) 92.3 89.3 92.8
Preoperative MELD score 16.6 ± 5.6 15.2 ± 2.1 15.4 ± 3.2
Worm ischemia time 64.8 ± 11.8 68.5 ± 10.0 62.4 ± 19.9
Gwbw ratio 1.3 ± 0.2 1.2 ± 0.3 1.3 ± 0.2
ICU admission hemoglobin (g dl) 9.8 ± 2.1 9.6 ± 1.7 10.0 ± 2.4
ICU admission hematocrite (%) 26.3 ± 4.3 25.9 ± 3.8 26.3 ± 4.8
Extubation time 3.7 ± 3.6 3.3 ± 1.7 3.2 ± 2.9
Patients receiving RBCs in ICU (%) 23.1 39.3 17.9
Patients receiving plasma in ICU (%) 33.3 35.7 32.1
Pleural eﬀusion 85.2% 85.7% 89.3%
Infections during ICU stay (%) 0.07 0.11 0.14
ICU stay (days) 6.1 ± 2.2 5.1 ± 2.5 5.3 ± 2.9
Three months patient’s survival (%) 85.2 89.3 85.7
Three months graft’s survival (%) 96.4 100 92.9
Data are expressed as mean ± standard deviation.
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Table 2 Hemodynamic data of the G-CVP (n= 17), G-SV (n= 18) and G-RV (n= 18) groups.
G-CVP, n= 17 G-SV, n= 18 G-RV, n= 18 Diﬀerence (95% CI) G-CVP and G-SV Diﬀerence (95% CI) G-C P and G-RV Diﬀerence (95% CI) G-SV and G-RV
HR Day 1 86.9 ± 6.5 86.1 ± 6.3 87.3 ± 7.9 0.80(5.25 to 6.85) 0.40(7.26 to 6.46) 1.20(7.97 to 5.57)
HR Day 2 84.1 ± 4.2 83.9 ± 5.1 83.6 ± 6.2 0.20(4.19 to 4.59) 0.50(4.44 to 5.44) 0.30(5.02 to 5.62)
HR Day 3 83.9 ± 3.2 82.8 ± 6.1 82.7 ± 4.4 1.10(3.44 to 5.64) 1.20(2.42 to 4.82) 0.10(4.88 to 5.08)
MAP Day 1 86.9 ± 8.2 91.8 ± 9.6 90.5 ± 13.1 4.89(13.28 to 3.49) 3.56(13.79 to 6.68) 1.33(9.45 to 12.11)
MAP Day 2 84.2 ± 11.8 91.4 ± 9.3 92.5 ± 10.6 7.14(17.13 to 2.85) 8.23(18.75 to 2.29) 1.09(10.48 to 8.30)
MAP Day 3 85.9 ± 8.6 91.8 ± 9.6 90.4 ± 12.9 5.96(14.54 to 2.62) 4.53(14.89 to 5.83) 1.43(9.30 to 12.17)
PCWP Day 1 8.2 ± 1.9 10.9 ± 1.9* 11.4 ± 2.2* 2.70(4.53 to 0.87) 3.20(5.16 to 1.24) 0.90(2.42 to 1.42)
PCWP Day 2 8.9 ± 1.5 11.7 ± 1.6* 12.4 ± 2.4* 2.80(4.29 to 1.31) 3.50(5.37 to 1.63) 0.70(2.61 to 1.21)
PCWP Day 3 8.6 ± 1.8 12.3 ± 1.6* 12.8 ± 1.6* 3.70(5.33 to 2.07) 4.20(5.83 to 2.57) 0.50(2.02 to 1.03)
RVEF Day 1 43.8 ± 4.4 46.1 ± 4.2 47.3 ± 6.9 2.30(6.34 to 1.74) 3.50(8.98 to 1.98) 1.20(6.61 to 4.21)
RVEF Day 2 45.1 ± 4.1 48.1 ± 3.3 48.4 ± 5.1 3.00(6.50 to 0.50) 3.30 (7.65 to 1.05) 0.30(4.31 to 3.72)
RVEF Day 3 47.3 ± 3.1 50.5 ± 4.2 47.3 ± 3.7 3.20(6.70 to 0.31) 1.90(5.12 to 1.32) 1.30(2.45 to 5.05)
SVRI Day 1 1343.2 ± 112.7 1349.3 ± 129.7 1437.8 ± 426.9 6.10(120.28 to 108.08) 94.60(387.99 to 198.7 ) 88.50(384.98 to 207.98)
SVRI Day 2 1331.5 ± 89.5 1416.5 ± 185.7 1299.8 ± 199.1 85.00(221.9 to 54.95) 31.70(113.32 to 176.72 116.70(64.17 to 297.57)
SVRI Day 3 1421.8 ± 238.6 1323.1 ± 198.4 1373.7 ± 221.9 98.70(107.45 to 304.85) 48.10(168.36 to 264.56 50.60(248.35 to 47.15)
PVRI Day 1 79.3 ± 7.5 84.8 ± 8.8 85.9 ± 10.6 3.50(11.2 to 4.18) 4.60(13.22 to 4.02) 1.10(10.28 to 8.08)
PVRI Day 2 83.2 ± 8.0 86.3 ± 8.7 88.1 ± 12.2 3.10(10.9 to 4.77) 4.90(4.63 to 4.83) 1.80(11.78 to 8.18)
PVRI Day 3 86.4 ± 6.7 87.9 ± 10.4 89.9 ± 8.6 1.50(9.71 to 6.71) 3.50(10.72 to 3.71) 2.00(10.97 to 6.97)
RVSWI Day 1 7.6 ± 0.9 8.1 ± 1.6 8.2 ± 1.9 0.56(1.71 to 0.68) 0.62(2.01 to 0.77) 0.06(1.72 to 1.59)
RVSWI Day 2 7.8 ± 0.9 8.2 ± 1.4 8.5 ± 1.4 0.35(1.49 to 0.79) 0.63(1.79 to 0.53) 0.28(1.62 to 1.06)
RVSWI Day 3 8.4 ± 0.7 8.9 ± 1.1 9.2 ± 1.4 0.52(1.38 to 0.34) 0.85(1.87 to 0.17) 0.33(1.49 to 0.84)
LVSWI Day 1 52.9 ± 4.7 48.7 ± 5.0 50.9 ± 4.4 4.20(0.39 to 8.79) 2.00(2.28 to 6.28) 2020(6.64 to 2.23)
LVSWI Day 2 52.9 ± 3.9 54.4 ± 5.2 54.6 ± 4.5 1.50(5.86 to 2.86) 1.70(5.69 to 2.290 0.20(4.79 to 4.39)
LVSWI Day 3 54.1 ± 3.9 56.3 ± 4.0 58.0 ± 3.1 2.20(5.93 to 1.53) 4.60(7.92 to 1.28) 3.90(7.87 to 0.07)
HR= heart rate, MAP=mean arterial pressure, PCWP= pulmonary capillary wedge pressure, RVEF = right ventricular ejection fraction, SVRI = systemic vascular resistance index,
PVRI = pulmonary vascular resistance index, RVSWI = right ventricular stroke work index, LVSWI = left ventricular stroke work ind . Data are expressed as mean ± standard deviation.
* P< 0.05 compared to the G-CVP group.
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228 A.M. Yassenalthough not statistically signiﬁcant, increased proportionally
with increased RVEDV in our trial indicating sound contrac-
tile functions. The preserved contractile functions will always
reduce the RVEDVI and hence, in this trial, the use of RVED-
VI as a guiding parameter led to increased volume of ﬂuid in-
fused compared to the use of CVP which is a pressure
parameter affected crucially by any change in myocardial com-
pliance that is always reduced in the early PO period after LTX
leading to rapid increase of CVP with infusion of lower vol-
umes of ﬂuid and delayed descent of the CVP value after the
bolus infusion.
Weather this reduction in the ﬂuid volume in the G-CVP
group compared to the other groups had a negative impact
on patient outcome or not is a crucial question. To answer this
question, two points had to be investigated. First is the hemo-
dynamic stability of the patients in the early PO days and sec-
ondly, is the impact of the ﬂuid protocol on graft and patient
outcome parameters. A comparable stable hemodynamic pro-
ﬁle in the three groups was achieved with the use of CVP to
guide ﬂuid therapy in our trial with the infusion of signiﬁcantly
lower ﬂuid volume compared to both G-SV and G-RV groups.
Increased volume infused in G-SV and G-RV compared to G-
CVP was not associated with signiﬁcant increase in the RVEF
in our trial. This lack of correlation between the volume in-
fused and the output represented by RVEF means that this ex-
tra ﬂuid volume is located on the plateau phase of the Frank–
Starling curve. Previous investigators demonstrated that after
a critical level of RVEDVI, any additional increase in the pre-
load will not generate a similar increase in the cardiac output
and hence, will not be of any beneﬁt to the patient [17].
In contradiction to our results, Paul and his co-workers, in
their systematic review, stated that the use of CVP to guide
ﬂuid replacement will increase the likelihood for development
of volume overload and pulmonary edema (ref icu ﬂuid 3).
However, on analyzing the studies enrolled in this systematic
review, it was found that 39.8% of the patients enrolled in
these studies underwent post coronary artery bypass surgery,
that is almost always associated with grave changes in the pul-
monary capillary permeability due to pro-inﬂammatory re-
sponse of the cardiopulmonary bypass machine [18] as well
as early post-operative changes in myocardial perfusion and
subsequently myocardial compliance and functions [19–21].
These changes negate the extrapolation of the results of the
systematic review done by Paul and his co-workers to post-
transplantation period investigated in our work.
There were no signiﬁcant differences between G-SV and G-
RV groups in any parameter in this trial. Other investigators
demonstrated a good correlation between SV and RVEDV
in several surgical settings in agreement with our ﬁndings
[22,23].
Mixed venous oxygen saturation and serum lactate are dy-
namic end points for hemodynamic and metabolic status after
LT. In this trial, neither of them demonstrated any signiﬁcant
differences between groups. A similar proﬁle was observed in
laboratory data reﬂecting graft and renal functions as well as
other outcome parameters like graft and patient survival rates,
infection rate or ICU stay. Although urine output was signif-
icantly higher in G-SV and G-RV groups compared to the
G-CVP group, yet, urine volume was within the accepted clin-
ical range in the three groups (>1 ml kg h1). These data indi-
cate a matching safety proﬁle of the three parameters used to
guide ﬂuid therapy. It could be concluded from our work that
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Table 4 Laboratory data of the G-CVP (n= 17), G-SV (n= 18) and G-RV (n= 18) groups.
G-CVP, n= 17 G-SV, n= 18 G-RV, n= 18 Diﬀerence (95% CI) G-CVP
and G-SV
Diﬀerence (95% CI) G-CVP
and G-RV
Diﬀerence (95% CI) G-SV
and G-RV
Createnine Day 1 1.0 ± 0.2 1.1 ± 0.2 1.0 ± 0.2 0.06(0.27 to 0.15) 0.02(0.24 to 0.19) 0.04(0.17 to 0.25)
Createnine Day 2 1.2 ± 0.2 1.1 ± 0.3 1.0 ± 0.3 0.11(0.13 to 0.35) 0.19(0.04 to 0.42) 0.08(0.17 to 0.33)
Createnine Day 3 0.9 ± 0.2 1.1 ± 0.2 0.9 ± 0.3 0.09(0.27 to 0.09) 0.03(0.23 to 0.17) 0.06(0.14 to 0.26)
Serum urea Day 1 49.6 ± 13.9 50.5 ± 10.9 50.4 ± 11.9 0.90(12.6 to 10.80) 0.80(12.92 to 11.32) 0.10(10.59 to 10.79)
Serum urea Day 2 47.6 ± 7.9 49.8 ± 8.8 48.1 ± 8.6 2.20(10.07 to 5.67) 0.50(8.26 to 7.27) 1.70(6.47 to 9.87)
Serum urea Day 3 46.9 ± 7.0 46.7 ± 7.8 47.0 ± 7.1 0.20(6.78 to 7.18) 0.10(6.75 to 6.55) 0.30(7.33 to 6.73)
Ph Day 1 7.4 ± 0.0 7.4 ± 0.1 7.4 ± 0.0 0.07(0.13 to 0.003) 0.06(0.12 to 0.0004) 0.02(0.02 to 0.07)
Ph Day 2 7.3 ± 0.0 7.3 ± 0.0 7.3 ± 0.0 0.005(0.02 to 0.01) 0.004(0.01 to 0.01) 0.00(0.01 to 0.01)
Ph Day 3 7.3 ± 0.0 7.3 ± 0.0 7.3 ± 0.0 0.006(0.00 to 0.02) 0.005(0.01 to 0.02) 0.00(0.01 to 0.01)
Paco2 Day 1 35.1 ± 3.8 34.1 ± 3.0 35.9 ± 2.8 1.00(2.21 to 4.21) 0.89(4.00 to 2.22) 1.89(4.59 to0.82)
Paco2 Day 2 35.7 ± 1.6 34.1 ± 1.9 34.7 ± 1.6 1.59(0.07 to 3.25) 0.95(0.56 to 2.46) 0.64(2.32 to1.04)
Paco2 Day 3 35.2 ± 1.6 34.5 ± 2.7 34.0 ± 3.4 0.23(2.34 to 1.88) 1.19(1.30 to 3.68) 1.42(1.47 to 4.310
Svo2 Day 1 84.9 ± 7.7 35.1 ± 8.2 84.8 ± 5.6 0.20(7.64 to 7.24) 0.10(6.19 to 6.39) 0.30(6.28 to 6.88)
Svo2 Day 2 80.0 ± 7.3 81.4 ± 7.6 80.5 ± 8.9 1.40(8.43 to 5.62) 0.50(8.18 to 7.18) 0.90(6.91 to 8.71)
Svo2 Day 3 75.8 ± 8.6 78.1 ± 10.5 81.9 ± 6.9 2.30(11.34 to 6.74) 6.10(13.42 to 1.22) 3.80(12.16 to4.56)
PaCo2 = plasma partial carbon dioxide tension and SvO2 = mixed venous oxygen saturation.
Data are expressed as mean ± standard deviation.
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230 A.M. Yassenadventitious in the ICU practice recently especially in this
overload-sensitive cohort.
The use of dynamic indices for assessment of preload and to
guide ﬂuid infusion could have added to the value of this trial
if used as a benchmark to compare the tested parameters, yet,
for logistic limitations, it was not applied in our study.
Another limitation in this trial was the lack of possibility of
assessment of myocardial contractility in the early PO period,
depraving the investigator from the possibility of having a
direct measurement of one of the main contributing factor in
generating the results of this trial. A trans- oesophygeal
echocardiography supported study is required to nullify the
limitations in our trial.
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